Kisqali

Chemical Nameribociclib
Dosage FormTablet (oral; 200 mg)
Drug ClassKinase inhibitors
SystemFemale reproductive
CompanyNovartis
Approval Year2017

Indication

  • To treat hormone receptor-positive human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy in conjunction with an aromatase inhibitor.
  • To treat hormone receptor-positive human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy or following disease progression on endocrine therapy in conjunction with Fulvestrant.
Last updated on 11/5/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kisqali (Ribociclib) Prescribing Information 2020Novartis Pharmaceuticals Corporation, East Hanover, NJ
Document TitleYearSource
NCCN guidelines updates: Breast cancer. 2018Journal of the National Comprehensive Cancer Network